Cardiac contraction motion compensation in gated myocardial perfusion SPECT: A comparative study

COVID-19 Pandemic Spurs Medical Telerobotic Systems: A Survey of Applications Requiring Physiological Organ Motion Compensation

The coronavirus disease 2019 (COVID-19) pandemic has resulted in public health interventions such as physical distancing restrictions to limit the spread and transmission of the novel coronavirus, causing significant effects on the delivery of physical healthcare procedures worldwide. The unprecedented pandemic spurs strong demand for intelligent robotic systems in healthcare. In particular, medical telerobotic systems can play a positive role in the provision of telemedicine to both COVID-19 and non-COVID-19 patients. Different from typical studies on medical teleoperation that consider problems such as time delay and information loss in long-distance communication, this survey addresses the consequences of physiological organ motion when using teleoperation systems to create physical distancing between clinicians and patients in the COVID-19 era. We focus on the control-theoretic approaches that have been developed to address inherent robot control issues associated with organ motion. The state-of-the-art telerobotic systems and their applications in COVID-19 healthcare delivery are reviewed, and possible future directions are outlined.

Real-time control of respiratory motion: Beyond radiation therapy

Motion management in radiation oncology is an important aspect of modern treatment planning and delivery. Special attention has been paid to control respiratory motion in recent years. However, other medical procedures related to both diagnosis and treatment are likely to benefit from the explicit control of breathing motion. Quantitative imaging - including increasingly important tools in radiology and nuclear medicine - is among the fields where a rapid development of motion control is most likely, due to the need for quantification accuracy. Emerging treatment modalities like focussed-ultrasound tumor ablation are also likely to benefit from a significant evolution of motion control in the near future. In the present article an overview of available respiratory motion systems along with ongoing research in this area is provided. Furthermore, an attempt is made to envision some of the most expected developments in this field in the near future.

Cardiac motion correction for improving perfusion defect detection in cardiac SPECT at standard and reduced doses of activity

In cardiac SPECT perfusion imaging, cardiac motion can lead to motion blurring of anatomical detail and perfusion defects in the reconstructed myocardium. In this study, we investigated the potential benefit of cardiac motion correction for improving the detectability of perfusion defects. We considered a post-reconstruction motion correction (PMC) approach in which the image motion between two cardiac gates is obtained with optical flow estimation. In the experiments, we demonstrated the proposed post-reconstruction motion correction with optical flow estimation (PMC-OFE) approach on a set of clinical acquisitions from 194 subjects. We quantified the detectability of perfusion defects in the reconstructed images by using the total perfusion deficit scores, calculated by the clinical software tool QPS, and conducted a receiver-operating-characteristic (ROC) study to obtain the detection performance. Besides imaging with conventional standard dose, we also evaluated the approach for reduced dose SPECT imaging where the imaging dose was retrospectively reduced to 50%, 25%, and 12.5% of the standard dose. The proposed PMC-OFE approach achieved at each dose level higher area-under-the-ROC-curve (AUC) for perfusion defect detection than the traditional approach of using ungated data (Non-MC) (p -value  <  0.05); in particular, with half dose, PMC-OFE achieved AUC  =  0.813, which is comparable to Non-MC with standard dose (AUC  =  0.795). Moreover, the proposed PMC-OFE approach also outperformed the 'Motion Frozen' (MF) method implemented in the clinical quantitative gated SPECT (QGS) software. In particular, at 25% and 12.5% of standard dose, the AUC values obtained by PMC-OFE are 0.788 and 0.779, respectively, compared to 0.758 and 0.731 for MF (p -value  <  0.05).